What is THP-00104 used for?

THP-00104 is indicated for Condition 1.

THP-00104 is developed by THPharm Corp..

What are the side effects of THP-00104?

Common side effects include Adverse event 1.

Last reviewed 2026-04-23 · How we verify

THP-00104

THPharm Corp. · Phase 3 active Small molecule

THP-00104 is a small molecule that targets the molecular target.

THP-00104 is a small molecule that targets the molecular target. Used for Condition 1.

At a glance

Generic name	THP-00104
Also known as	Placebo of Fociga Tab. 10mg
Sponsor	THPharm Corp.
Target	molecular target
Modality	Small molecule
Phase	Phase 3

Mechanism of action

The exact mechanism of action of THP-00104 is not well understood, but it is believed to work by binding to the molecular target and modulating its activity.

Approved indications

Condition 1

Common side effects

Adverse event 1

Key clinical trials

A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THP-00102, and THP-00103 in Subjects With T2DM and Essential Hypertension (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

THP-00104 CI brief — competitive landscape report
THP-00104 updates RSS · CI watch RSS
THPharm Corp. portfolio CI